To overcome these limitations, recently a new potent MDM2 inhibitor RG7388, also known as Idasanutlin, has been discovered (Ding et al., 2013) and actually entered in a phase 1/1b study in relapsed/refractory AML. Here, MDM2 is linked to acute myeloid leukemia.